| Drug General Information |
| Drug ID |
D0MW3H
|
| Former ID |
DNC003574
|
| Drug Name |
CIPEMASTAT
|
| Drug Type |
Small molecular drug
|
| Indication |
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]
|
Phase 3 |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C22H36N4O5
|
| InChI |
InChI=1S/C22H36N4O5/c1-22(2)20(29)26(21(30)24(22)3)14-17(18(27)23-31)16(13-15-9-5-6-10-15)19(28)25-11-7-4-8-12-25/h15-17,31H,4-14H2,1-3H3,(H,23,27)/t16-,17+/m1/s1
|
| InChIKey |
GFUITADOEPNRML-SJORKVTESA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
14783449, 14856881, 17397651, 24127178, 44922488, 50185748, 57373439, 85148104, 103339279, 127947718, 135698228, 142342525, 163126224, 178103080, 180371968, 198968231, 204360707, 225055683, 232744030, 241376166, 249617711, 250135048, 252156872
|
| Target and Pathway |
| Target(s) |
Neutrophil collagenase |
Target Info |
Modulator |
[1]
|
|---|
| Interstitial collagenase |
Target Info |
Modulator |
[1]
|
|
KEGG Pathway
|
PPAR signaling pathway
|
|
Pathways in cancer
|
|
Bladder cancer
|
|
Rheumatoid arthritis
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
TWEAK Signaling Pathway
|
|
Wnt Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathwayP00004:Alzheimer disease-presenilin pathway
|
|
Plasminogen activating cascade
|
|
Pathway Interaction Database
|
Endothelins
|
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
|
Glucocorticoid receptor regulatory network
|
|
AP-1 transcription factor network
|
|
Syndecan-1-mediated signaling events
|
|
Reactome
|
Collagen degradation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix MetalloproteinasesR-HSA-1442490:Collagen degradation
|
|
Activation of Matrix Metalloproteinases
|
|
Basigin interactions
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
WikiPathways
|
Activation of Matrix Metalloproteinases
|
|
Matrix MetalloproteinasesWP366:TGF beta Signaling Pathway
|
|
Bladder Cancer
|
|
Degradation of collagen
|
|
Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Cell surface interactions at the vascular wall
|
|
Matrix Metalloproteinases
|
| References |
| REF 1 | Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6466). |
|---|
